RAS70 peptide targets multiforme glioblastoma by binding to the plasma membrane heat shock protein HSP70.
Saved in:
| Title: | RAS70 peptide targets multiforme glioblastoma by binding to the plasma membrane heat shock protein HSP70. |
|---|---|
| Authors: | Shevtsov M; Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.; Personalized Medicine Centre, Almazov National Medical Research Centre, St. Petersburg, Russia.; Laboratory of Biomedical Nanotechnologies, Institute of Cytology of the Russian Academy of Sciences (RAS), St. Petersburg, Russia., Yudintceva N; Personalized Medicine Centre, Almazov National Medical Research Centre, St. Petersburg, Russia.; Laboratory of Biomedical Nanotechnologies, Institute of Cytology of the Russian Academy of Sciences (RAS), St. Petersburg, Russia., Bobkov D; Personalized Medicine Centre, Almazov National Medical Research Centre, St. Petersburg, Russia.; Laboratory of Biomedical Nanotechnologies, Institute of Cytology of the Russian Academy of Sciences (RAS), St. Petersburg, Russia.; Smorodintsev Research Institute of Influenza, St. Petersburg, Russia., Likhomanova R; Personalized Medicine Centre, Almazov National Medical Research Centre, St. Petersburg, Russia.; Laboratory of Biomedical Nanotechnologies, Institute of Cytology of the Russian Academy of Sciences (RAS), St. Petersburg, Russia., Nechaeva A; Personalized Medicine Centre, Almazov National Medical Research Centre, St. Petersburg, Russia., Mikhailova E; Personalized Medicine Centre, Almazov National Medical Research Centre, St. Petersburg, Russia., Oganesyan E; Personalized Medicine Centre, Almazov National Medical Research Centre, St. Petersburg, Russia., Fedorov V; Personalized Medicine Centre, Almazov National Medical Research Centre, St. Petersburg, Russia., Kurkin A; Laboratory of Biomedical Nanotechnologies, Institute of Cytology of the Russian Academy of Sciences (RAS), St. Petersburg, Russia., Lukacheva A; Personalized Medicine Centre, Almazov National Medical Research Centre, St. Petersburg, Russia.; Laboratory of Biomedical Nanotechnologies, Institute of Cytology of the Russian Academy of Sciences (RAS), St. Petersburg, Russia., Fofanov G; Personalized Medicine Centre, Almazov National Medical Research Centre, St. Petersburg, Russia., Kim A; Personalized Medicine Centre, Almazov National Medical Research Centre, St. Petersburg, Russia., Fedorov E; Personalized Medicine Centre, Almazov National Medical Research Centre, St. Petersburg, Russia., Sitovskaya D; Polenov Neurosurgical Institute, Almazov National Medical Research Centre, St. Petersburg, Russia., Ulitin A; Polenov Neurosurgical Institute, Almazov National Medical Research Centre, St. Petersburg, Russia., Mikhailova N; Personalized Medicine Centre, Almazov National Medical Research Centre, St. Petersburg, Russia., Anufriev I; Personalized Medicine Centre, Almazov National Medical Research Centre, St. Petersburg, Russia., Istomina M; Personalized Medicine Centre, Almazov National Medical Research Centre, St. Petersburg, Russia., Murashko E; Personalized Medicine Centre, Almazov National Medical Research Centre, St. Petersburg, Russia., Kessenikh E; Personalized Medicine Centre, Almazov National Medical Research Centre, St. Petersburg, Russia., Aksenov N; Laboratory of Biomedical Nanotechnologies, Institute of Cytology of the Russian Academy of Sciences (RAS), St. Petersburg, Russia., Vakhitova Y; Personalized Medicine Centre, Almazov National Medical Research Centre, St. Petersburg, Russia., Samochernykh K; Personalized Medicine Centre, Almazov National Medical Research Centre, St. Petersburg, Russia.; Polenov Neurosurgical Institute, Almazov National Medical Research Centre, St. Petersburg, Russia., Pitkin E; Department of Statistics and Data Science, Wharton School, University of Pennsylvania, Philadelphia, PA, United States., Shlyakhto E; Personalized Medicine Centre, Almazov National Medical Research Centre, St. Petersburg, Russia., Combs SE; Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany. |
| Source: | Frontiers in oncology [Front Oncol] 2025 Mar 24; Vol. 15, pp. 1543657. Date of Electronic Publication: 2025 Mar 24 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
